Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (5563)	10/21/1998 9:20:00 AM
From: margie	Read Replies (1) \| Respond to of 6136

BTW, last night, Bob Pisani on CNBC said that Agouron beat First Call estimates by .04 cents. He referred to Agouron as "one of those designer" companies, or maybe he said they make "designer" drugs. and Briefing Com reported that: <Agouron Pharmaceuticals (AGPH) 36 7/8 unch: company reports Q1 net of $0.21 a share, 4 cents above the First Call mean estimate, vs yr-ago earnings of $0.11.. Elise Wang congratulated Agouron and also thanked them for meeting her numbers :-) And I don't think I said you were short, Alexander. I just thought you were "looking for information in all the wrong places." So much for Whisper numbers etc...

To: margie who wrote (5563)	10/21/1998 10:29:00 AM
From: Zirdu	Respond to of 6136

Margie, thanks very much for the excellent summary of the conference call.

To: margie who wrote (5563)	10/21/1998 1:01:00 PM
From: billkirn	Respond to of 6136

Margie: Nice work, thank you. I almost hate to say this, but we are looking pretty solid allowing some upward bias and movement. Bill

To: margie who wrote (5563)	10/21/1998 1:08:00 PM
From: Joe E.	Respond to of 6136

margie: Thanks for the conference call summary.

To: margie who wrote (5563)	10/21/1998 5:11:00 PM
From: Izzy	Read Replies (2) \| Respond to of 6136

Rick (or anyone): Any comment regarding AG1766 protease inhibitor (RE: Post 5563)? We've mentioned this before and it was my previous understanding that AGPH was attempting to improve Viracept. Is this a new PI? Do you have any info? I can't find out anything about it and I haven't seen it referenced before as AG1766. I assume that this is not the PI from Japan. Potentially, that would mean that AGPH will have 2 PIs, one NNRTI, and Remune on the market as early as mid-late 1999. Does this imply that "AGPH General" will actually end up being a monster HIV drug powerhouse? And it seems strange to me that there has been no mention of the oncology division spinoff. Also, I haven't received the shareholders' meeting package yet. Has anyone else received it?